Production (Stage)
Terns Pharmaceuticals, Inc.
TERN
$3.02
$0.082.72%
NASDAQ
03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
---|---|---|---|---|---|
Revenue | -- | -- | -- | -- | -- |
Total Other Revenue | -- | -- | -- | -- | -- |
Total Revenue | -- | -- | -- | -- | -- |
Cost of Revenue | -- | -- | -- | -- | -- |
Gross Profit | -- | -- | -- | -- | -- |
SG&A Expenses | -13.43% | -18.69% | -21.28% | 53.47% | 62.94% |
Depreciation & Amortization | -- | -- | -- | -- | -- |
Other Operating Expenses | -- | -- | -- | -- | -- |
Total Operating Expenses | 0.00% | -0.67% | 4.88% | 36.24% | 43.51% |
Operating Income | 0.00% | 0.67% | -4.88% | -36.24% | -43.51% |
Income Before Tax | 0.71% | 1.53% | -3.90% | -33.56% | -34.08% |
Income Tax Expenses | -9.06% | 8.79% | -47.05% | -42.76% | -30.48% |
Earnings from Continuing Operations | 0.73% | 1.50% | -3.60% | -33.07% | -33.71% |
Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
Minority Interest in Earnings | -- | -- | -- | -- | -- |
Net Income | 0.73% | 1.50% | -3.60% | -33.07% | -33.71% |
EBIT | 0.00% | 0.67% | -4.88% | -36.24% | -43.51% |
EBITDA | -0.01% | 0.70% | -4.88% | -36.45% | -43.93% |
EPS Basic | 13.56% | 10.99% | 6.81% | -2.12% | 20.62% |
Normalized Basic EPS | 13.53% | 11.02% | 6.47% | -2.48% | 20.50% |
EPS Diluted | 13.56% | 10.99% | 6.81% | -2.12% | 20.62% |
Normalized Diluted EPS | 13.53% | 11.02% | 6.47% | -2.48% | 20.50% |
Average Basic Shares Outstanding | 15.66% | 11.55% | 11.83% | 24.91% | 53.82% |
Average Diluted Shares Outstanding | 15.66% | 11.55% | 11.83% | 24.91% | 53.82% |
Dividend Per Share | -- | -- | -- | -- | -- |
Payout Ratio | -- | -- | -- | -- | -- |